Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on February 15, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "JAGX". The report addresses a critical regulatory event regarding the Company's continued listing status on Nasdaq.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point provided is the stock price performance triggering the delisting notice:
- Stock Price: As of February 14, 2024, the closing bid price was $0.10 or less for 10 consecutive trading days.
- Compliance Threshold: The Company failed to meet the Nasdaq Minimum Bid Price Requirement of $1.00 per share.
Material Changes and Delisting Notice
The Company received a notification from the Nasdaq Listing Qualifications Staff on February 15, 2024, determining that its securities will be delisted from Nasdaq effective at the opening of business on February 26, 2024. This determination follows a history of non-compliance:
- Initial Notice: May 10, 2023 (bid price below $1.00 for 30 days).
- Grace Periods: The Company was granted two 180-day grace periods, the second expiring on May 6, 2024.
- Low Priced Stocks Rule: The current delisting determination is based on Nasdaq Listing Rule 5810(c)(3)(A)(iii) due to the stock trading at $0.10 or less for 10 consecutive days.
Outlook, Risks, and Management Commentary
The Company intends to consider available options to resolve the deficiency and regain compliance. Management notes the following regarding the appeal process:
- Appeal Deadline: The Company may request a hearing before the Nasdaq Hearings Panel on or prior to February 22, 2024.
- Trading Status: If an appeal is requested, the delisting is stayed, and the stock will continue to trade on Nasdaq pending the Panel's final decision.
- Uncertainty: There is no assurance that the Panel will grant an extension period to regain compliance.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations, referencing risks detailed in the 2022 Form 10-K.
Investor Verification Checklist
- Verify whether Jaguar Health, Inc. files a hearing request with the Nasdaq Hearings Panel by February 22, 2024.
- Monitor the outcome of the appeal hearing to determine if the delisting is stayed or if an extension is granted.
- Review the Company's 2022 Form 10-K for detailed risk factors and financial condition context not included in this 8-K.
- Check for subsequent filings regarding the Company's plan to regain compliance with the $1.00 minimum bid price requirement.